NCT05885451View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 29, 2019

Primary Completion Date

April 11, 2019

Study Completion Date

April 11, 2019

Conditions
Chronic Graft-versus-Host Disease (cGVHD)
Interventions
DRUG

AMG 592

Administered as SC injection

OTHER

Placebo

Administered as SC injection

Trial Locations (1)

2031

Research Site, Randwick

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT05885451 - A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants | Biotech Hunter | Biotech Hunter